Skip to main content

Table 6 QALY and (percent patient value gains) for triple combination therapy cohorts associated with zeaxanthin use and with no zeaxanthin use

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Model

TTZ vs. control cohort

TT vs. control cohort

TTZ vs. TT

First-eye model

0.453 (6.7 %)

0.339 (5.0 %)

0.115 (1.6 %)

Second-eye model

0.653 (14.1 %)

0.400 (8.7 %)

0.253 (5.0 %)

Combined-eye model

0.521 (8.2 %)

0.359 (6.0 %)

0.162 (2.5 %)

Combined-eye model

p < 0.0001

p < 0.0001

p < 0.0001

  1. TTZ triple therapy with zeaxanthin, TT triple therapy
  2. Combined-eye model = 66 % first-eye model and 34 % second-eye model, Zeaxanthin = Zx